{"doi":"10.1093/jnci/djs353","title":"When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression","abstract":null,"journal":"JNCI Journal of the National Cancer Institute","year":2012,"id":19870,"datarank":7.869536302200448,"base_score":4.8283137373023015,"endowment":4.8283137373023015,"self_citation_contribution":0.7242470605953454,"citation_network_contribution":7.145289241605102,"self_endowment_contribution":0.7242470605953454,"citer_contribution":7.145289241605102,"corpus_percentile":null,"corpus_rank":null,"citation_count":124,"citer_count":117,"citers_with_citation_signal":102,"citers_with_endowment":102,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":133240,"name":"M. J. Morris","orcid":null,"position":1,"is_corresponding":false},{"id":133241,"name":"F. S. Hodi","orcid":null,"position":2,"is_corresponding":false},{"id":133242,"name":"L. H. Baker","orcid":null,"position":3,"is_corresponding":false},{"id":133243,"name":"M. G. Kris","orcid":null,"position":4,"is_corresponding":false},{"id":133244,"name":"A. P. Venook","orcid":null,"position":5,"is_corresponding":false},{"id":133245,"name":"L. H. Schwartz","orcid":null,"position":6,"is_corresponding":false},{"id":133239,"name":"G. R. Oxnard","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":4.8283137373023015,"endowment":4.8283137373023015,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"22927506","pmcid":"PMC3708548","openalex_id":"https://openalex.org/W2110647409","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"U10 CA032102","title":null}],"total_grants":1,"fwci":4.2074,"citation_percentile":0.94252153,"influential_citations":1,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":6},{"year":2014,"count":17},{"year":2015,"count":13},{"year":2016,"count":16},{"year":2017,"count":10},{"year":2018,"count":11},{"year":2019,"count":8},{"year":2020,"count":8},{"year":2021,"count":12},{"year":2022,"count":6},{"year":2023,"count":6},{"year":2024,"count":5},{"year":2026,"count":2}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://academic.oup.com/jnci/article-pdf/104/20/1534/8095669/djs353.pdf","host_type":"journal"},{"url":"https://academic.oup.com/jnci/article-pdf/104/20/1534/8095669/djs353.pdf","host_type":"BRONZE"},{"url":"https://academic.oup.com/jnci/article-pdf/104/20/1534/8095669/djs353.pdf","host_type":"publisher"},{"url":"http://academic.oup.com/jnci/article-pdf/104/20/1534/8095669/djs353.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1093/jnci/djs353","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/22927506","host_type":"repository"},{"url":"https://escholarship.org/uc/item/0sx610z3","host_type":"repository"},{"url":"http://europepmc.org/articles/PMC3708548","host_type":"repository"},{"url":"http://jnci.oxfordjournals.org/cgi/content/short/djs353v1","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3708548","host_type":"repository"}],"fields_of_study":["Cancer Genomics and Diagnostics","Lung Cancer Treatments and Mutations","Pancreatic and Hepatic Oncology Research","Medicine","Antibodies, Monoclonal","Antineoplastic Agents","Clinical Trials as Topic","Disease Progression","Disease-Free Survival","ErbB Receptors","Humans","Ipilimumab","Lung Neoplasms","Male","Neoplasms","Nivolumab","Prostate-Specific Antigen","Prostatic Neoplasms","Research Design","Treatment Failure","Treatment Outcome"],"mesh_terms":["Ipilimumab","Nivolumab","Antibodies, Monoclonal","Antineoplastic Agents","Clinical Trials as Topic","Humans","Lung Neoplasms","Male","Neoplasms","Prostatic Neoplasms","Research Design","Treatment Outcome","Treatment Failure","Prostate-Specific Antigen","Disease Progression","Disease-Free Survival","ErbB Receptors"],"keywords":["Tumor progression","Surrogate endpoint","Clinical endpoint","Medicine","Clinical trial","Progression-free survival","Oncology","Disease","Intensive care medicine","Internal medicine","Endpoint Determination","Overall survival","Cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-04T06:06:16.902270Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}